HC Wainwright Has Positive Forecast for CRSP FY2026 Earnings

CRISPR Therapeutics AG (NASDAQ:CRSP) – Research analysts at HC Wainwright upped their FY2026 EPS estimates for shares of CRISPR Therapeutics in a report issued on Wednesday, August 5th. HC Wainwright analyst M. Kapoor now forecasts that the company will post earnings of ($4.53) per share for the year, up from their previous estimate of ($4.67). HC Wainwright has a “Buy” rating and a $80.00 price target on the stock. The consensus estimate for CRISPR Therapeutics’ current full-year earnings is ($4.65) per share. HC Wainwright also issued estimates for CRISPR Therapeutics’ Q4 2027 earnings at ($1.24) EPS and FY2027 earnings at ($4.98) EPS.

Several other research analysts also recently weighed in on the stock. Citizens Jmp restated a “market outperform” rating and set a $80.00 price target on shares of CRISPR Therapeutics in a research report on Monday, July 6th. UBS Group set a $80.00 price objective on CRISPR Therapeutics in a report on Friday, June 12th. The Goldman Sachs Group reiterated a “neutral” rating and set a $55.00 price objective on shares of CRISPR Therapeutics in a research note on Thursday. Morgan Stanley set a $60.00 target price on CRISPR Therapeutics and gave the company an “equal weight” rating in a report on Thursday, June 11th. Finally, Sanford C. Bernstein raised their target price on CRISPR Therapeutics from $50.00 to $56.00 and gave the company a “market perform” rating in a research report on Wednesday, May 13th. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $68.06.

CRISPR Therapeutics Stock Down 1.5%

Shares of NASDAQ CRSP opened at $51.64 on Friday. The firm has a market cap of $4.99 billion, a price-to-earnings ratio of -10.85 and a beta of 1.74. The company’s 50-day simple moving average is $52.42 and its 200-day simple moving average is $52.30. The company has a quick ratio of 17.96, a current ratio of 17.85 and a debt-to-equity ratio of 0.34. CRISPR Therapeutics has a 52-week low of $44.12 and a 52-week high of $78.48.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings data on Tuesday, June 30th. The company reported ($0.94) earnings per share for the quarter. The company had revenue of $10.18 million for the quarter. CRISPR Therapeutics had a negative return on equity of 24.39% and a negative net margin of 3,368.72%.

Institutional Trading of CRISPR Therapeutics

Several large investors have recently bought and sold shares of CRSP. Handelsbanken Fonder AB raised its holdings in CRISPR Therapeutics by 30.1% in the 2nd quarter. Handelsbanken Fonder AB now owns 35,000 shares of the company’s stock valued at $1,909,000 after acquiring an additional 8,100 shares during the last quarter. Hennion & Walsh Asset Management Inc. boosted its holdings in shares of CRISPR Therapeutics by 16.9% during the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 30,485 shares of the company’s stock worth $1,663,000 after purchasing an additional 4,407 shares during the last quarter. Valeo Financial Advisors LLC purchased a new stake in shares of CRISPR Therapeutics in the second quarter valued at approximately $201,000. Thurston Springer Miller Herd & Titak Inc. grew its position in shares of CRISPR Therapeutics by 184.2% in the second quarter. Thurston Springer Miller Herd & Titak Inc. now owns 1,637 shares of the company’s stock valued at $89,000 after purchasing an additional 1,061 shares in the last quarter. Finally, Quad Cities Investment Group LLC purchased a new stake in shares of CRISPR Therapeutics in the second quarter valued at approximately $227,000. Hedge funds and other institutional investors own 69.20% of the company’s stock.

Insider Activity at CRISPR Therapeutics

In other news, insider Naimish Patel sold 3,786 shares of the firm’s stock in a transaction dated Friday, May 29th. The shares were sold at an average price of $55.62, for a total value of $210,577.32. Following the transaction, the insider directly owned 19,357 shares of the company’s stock, valued at approximately $1,076,636.34. This trade represents a 16.36% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 5.20% of the stock is owned by company insiders.

CRISPR Therapeutics News Roundup

Here are the key news stories impacting CRISPR Therapeutics this week:

• Positive Sentiment: Piper Sandler reaffirmed its Buy rating, signaling continued confidence in CRISPR Therapeutics’ development pipeline and long-term commercial potential. Piper Sandler Reaffirms Their Buy Rating on CRISPR Therapeutics AG
• Positive Sentiment: Bullish commentary highlighted potential CASGEVY sales growth and expansion into in vivo gene editing through CTX310, which could broaden CRSP’s future revenue opportunities if clinical and commercial milestones are achieved. CRISPR Strong Buy CASGEVY Sales Growth and In Vivo Expansion With CTX310
• Neutral Sentiment: Brookline Capital Markets made mixed revisions: its Q3 2026 loss estimate improved slightly to $1.30 per share from $1.31, while its FY2027 loss estimate improved to $4.51 from $5.05. However, the firm still expects CRSP to remain unprofitable in 2026 and 2027.
• Negative Sentiment: Brookline reduced its Q4 2026 EPS estimate to a loss of $1.87 from $1.69 and lowered its FY2026 estimate to a loss of $5.63 from $5.36. Both forecasts are weaker than the broader current-year consensus loss estimate of $4.90, potentially weighing on sentiment.
• Negative Sentiment: The same analyst modestly cut projected profits for FY2028, FY2029 and FY2030, suggesting a slightly less optimistic view of CRSP’s long-term earnings ramp. Despite those reductions, the estimates still imply a transition from losses to profitability beginning in FY2028.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.